{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T08:25:30Z","timestamp":1768465530694,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24KJ1842"],"award-info":[{"award-number":["24KJ1842"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H03095"],"award-info":[{"award-number":["21H03095"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008702","name":"Kagoshima University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008702","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To comprehensively evaluate baseline characteristics of patients with central serous chorioretinopathy (CSC) and develop predictive risk scores to identify visual prognosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This single-institute, retrospective cohort study included 144 eyes of 144 patients with CSC who underwent photodynamic therapy and achieved serous retinal detachment resolution. We developed and assessed the performance of several risk scores for best-corrected visual acuity (BCVA) outcomes six months post-treatment: i) BCVA improvement (\u2264-1.0 logMAR), and ii) BCVA deterioration (\u2265+\u20091.0 logMAR).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The BCVA improvement models used photoreceptor outer segment thickness, loss of photoreceptor outer segment, and neurosensory retinal thickness (NSRT), while the BCVA deterioration models included outer nuclear layer thickness and NSRT. The BCVA improvement models demonstrated a corrected area under the curve (AUC) of 0.786 (95% confidence interval [CI]: 0.699\u20130.864), with 80.4% sensitivity, and 71.2% specificity. The BCVA deterioration models achieved a corrected AUC of 0.864 (95% CI: 0.742\u20130.958), with 85.7% sensitivity, and 83.5% specificity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The predictive models for CSC exhibited favorable performance in predicting individual visual prognoses. A thinner outer nuclear layer may be associated with BCVA deterioration, whereas preservation of the photoreceptor outer segment may be correlated with BCVA improvement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Key Messages<\/jats:title>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>\n              <jats:italic>What is known<\/jats:italic>\n            <\/jats:title>\n            <jats:p>\n              <jats:list list-type=\"bullet\">\n                <jats:list-item>\n                  <jats:p>Pre-treatment best-corrected visual acuity, thickness of each sensory retinal layer, time from\u00a0onset to treatment, and macular atrophy were each found to be associated with visual\u00a0prognosis for patients with central serous chorioretinopathy (CSC).<\/jats:p>\n                <\/jats:list-item>\n              <\/jats:list>\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>\n              <jats:italic>What is new<\/jats:italic>\n            <\/jats:title>\n            <jats:p>\n              <jats:list list-type=\"bullet\">\n                <jats:list-item>\n                  <jats:p>The current study comprehensively assessed potential prognostic factors and precisely identified individual likelihood of visual prognosis.<\/jats:p>\n                <\/jats:list-item>\n                <jats:list-item>\n                  <jats:p>The study found that different regions of the sensory retina were associated with either worsening or improving visual acuity.<\/jats:p>\n                <\/jats:list-item>\n                <jats:list-item>\n                  <jats:p>Accurately predicting visual outcomes after photodynamic therapy for CSC would help healthcare providers create personalized treatment plans and enable patients to make informed decisions about their treatment based on their expected visual results.<\/jats:p>\n                <\/jats:list-item>\n              <\/jats:list>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00417-024-06698-1","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T09:07:27Z","timestamp":1732266447000},"page":"705-711","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictive risk scores for visual prognosis after photodynamic therapy for central serous chorioretinopathy"],"prefix":"10.1007","volume":"263","author":[{"given":"Ryoh","family":"Funatsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroto","family":"Terasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohisa","family":"Mihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Shiihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shozo","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiji","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"key":"6698_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ophtha.2007.02.032","volume":"115","author":"AS Kitzmann","year":"2008","unstructured":"Kitzmann AS, Pulido JS, Diehl NN et al (2008) The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980\u20132002. Ophthalmology 115:169\u2013173. https:\/\/doi.org\/10.1016\/j.ophtha.2007.02.032","journal-title":"Ophthalmology"},{"key":"6698_CR2","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/s0161-6420(96)30386-2","volume":"103","author":"RF Spaide","year":"1996","unstructured":"Spaide RF, Campeas L, Haas A et al (1996) Central serous chorioretinopathy in younger and older adults. Ophthalmology 103:2070\u20132079 discussion 2079-80. https:\/\/doi.org\/10.1016\/s0161-6420(96)30386-2","journal-title":"Ophthalmology"},{"key":"6698_CR3","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2018.12.048","volume":"126","author":"S Mrejen","year":"2019","unstructured":"Mrejen S, Balaratnasingam C, Kaden TR et al (2019) Long-term visual outcomes and causes of Vision loss in Chronic Central Serous Chorioretinopathy. Ophthalmology 126:576\u2013588. https:\/\/doi.org\/10.1016\/j.ophtha.2018.12.048","journal-title":"Ophthalmology"},{"key":"6698_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ajo.2020.10.011","volume":"223","author":"E Borrelli","year":"2021","unstructured":"Borrelli E, Battista M, Sacconi R et al (2021) OCT risk factors for 3-Year Development of Macular Complications in eyes with resolved chronic Central Serous Chorioretinopathy. Am J Ophthalmol 223:129\u2013139. https:\/\/doi.org\/10.1016\/j.ajo.2020.10.011","journal-title":"Am J Ophthalmol"},{"key":"6698_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ajo.2021.06.020","volume":"233","author":"TJ van Rijssen","year":"2022","unstructured":"van Rijssen TJ, van Dijk EHC, Tsonaka R et al (2022) Half-dose photodynamic therapy Versus Eplerenone in Chronic Central Serous Chorioretinopathy (SPECTRA): a Randomized Controlled Trial. Am J Ophthalmol 233:101\u2013110. https:\/\/doi.org\/10.1016\/j.ajo.2021.06.020","journal-title":"Am J Ophthalmol"},{"key":"6698_CR6","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.ophtha.2018.04.021","volume":"125","author":"EHC van Dijk","year":"2018","unstructured":"van Dijk EHC, Fauser S, Breukink MB et al (2018) Half-dose photodynamic therapy versus high-density Subthreshold Micropulse Laser treatment in patients with Chronic Central Serous Chorioretinopathy: the PLACE trial. Ophthalmology 125:1547\u20131555. https:\/\/doi.org\/10.1016\/j.ophtha.2018.04.021","journal-title":"Ophthalmology"},{"key":"6698_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ajo.2020.04.007","volume":"216","author":"TJ van Rijssen","year":"2020","unstructured":"van Rijssen TJ, van Dijk EHC, Scholz P et al (2020) Crossover to photodynamic therapy or Micropulse Laser after failure of primary treatment of Chronic Central Serous Chorioretinopathy: the REPLACE Trial. Am J Ophthalmol 216:80\u201389. https:\/\/doi.org\/10.1016\/j.ajo.2020.04.007","journal-title":"Am J Ophthalmol"},{"key":"6698_CR8","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.ophtha.2013.09.024","volume":"121","author":"SH Bae","year":"2014","unstructured":"Bae SH, Heo J, Kim C et al (2014) Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial. Ophthalmology 121:558\u2013565. https:\/\/doi.org\/10.1016\/j.ophtha.2013.09.024","journal-title":"Ophthalmology"},{"key":"6698_CR9","doi-asserted-by":"publisher","first-page":"100152","DOI":"10.1016\/j.xops.2022.100152","volume":"2","author":"N Aisu","year":"2022","unstructured":"Aisu N, Miyake M, Hosoda Y et al (2022) Effectiveness of reduced-fluence photodynamic therapy for Chronic Central Serous Chorioretinopathy: a propensity score analysis. Ophthalmol Sci 2:100152. https:\/\/doi.org\/10.1016\/j.xops.2022.100152","journal-title":"Ophthalmol Sci"},{"key":"6698_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ajo.2023.04.016","volume":"253","author":"R Funatsu","year":"2023","unstructured":"Funatsu R, Terasaki H, Sonoda S et al (2023) A photodynamic therapy index for Central Serous Chorioretinopathy to Predict Visual Prognosis using pretreatment factors. Am J Ophthalmol 253:86\u201395. https:\/\/doi.org\/10.1016\/j.ajo.2023.04.016","journal-title":"Am J Ophthalmol"},{"key":"6698_CR11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ajo.2023.05.022","volume":"256","author":"R Funatsu","year":"2023","unstructured":"Funatsu R, Terasaki H, Sonoda S et al (2023) Characteristics related to visual acuity loss after successful photodynamic therapy for eyes with Central Serous Chorioretinopathy. Am J Ophthalmol 256:164\u2013174. https:\/\/doi.org\/10.1016\/j.ajo.2023.05.022","journal-title":"Am J Ophthalmol"},{"key":"6698_CR12","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s00417-009-1104-8","volume":"247","author":"JW Moon","year":"2009","unstructured":"Moon JW, Yu HG, Kim TW et al (2009) Prognostic factors related to photodynamic therapy for central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 247:1315\u20131323. https:\/\/doi.org\/10.1007\/s00417-009-1104-8","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6698_CR13","doi-asserted-by":"publisher","unstructured":"Wakatsuki Y, Tanaka K, Mori R et al (2021) Morphological changes and prognostic factors before and after photodynamic therapy for Central Serous Chorioretinopathy. https:\/\/doi.org\/10.3390\/ph14010053. Pharmaceuticals 14:","DOI":"10.3390\/ph14010053"},{"key":"6698_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40123-020-00250-0","volume":"9","author":"EHC van Dijk","year":"2020","unstructured":"van Dijk EHC, van Rijssen TJ, Subhi Y, Boon CJF (2020) Photodynamic therapy for Chorioretinal diseases: a practical Approach. Ophthalmol Ther 9:329\u2013342. https:\/\/doi.org\/10.1007\/s40123-020-00250-0","journal-title":"Ophthalmol Ther"},{"key":"6698_CR15","doi-asserted-by":"publisher","first-page":"100770","DOI":"10.1016\/j.preteyeres.2019.07.003","volume":"73","author":"TJ van Rijssen","year":"2019","unstructured":"van Rijssen TJ, van Dijk EHC, Yzer S et al (2019) Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res 73:100770. https:\/\/doi.org\/10.1016\/j.preteyeres.2019.07.003","journal-title":"Prog Retin Eye Res"},{"key":"6698_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ajo.2009.01.018","volume":"148","author":"H Matsumoto","year":"2009","unstructured":"Matsumoto H, Sato T, Kishi S (2009) Outer nuclear layer thickness at the fovea determines visual outcomes in resolved central serous chorioretinopathy. Am J Ophthalmol 148:105\u201310e1. https:\/\/doi.org\/10.1016\/j.ajo.2009.01.018","journal-title":"Am J Ophthalmol"},{"key":"6698_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ajo.2004.08.037","volume":"139","author":"FC Piccolino","year":"2005","unstructured":"Piccolino FC, de la Longrais RR, Ravera G et al (2005) The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy. Am J Ophthalmol 139:87\u201399. https:\/\/doi.org\/10.1016\/j.ajo.2004.08.037","journal-title":"Am J Ophthalmol"},{"key":"6698_CR18","doi-asserted-by":"publisher","first-page":"20446","DOI":"10.1038\/s41598-021-99977-4","volume":"11","author":"M Pfau","year":"2021","unstructured":"Pfau M, van Dijk EHC, van Rijssen TJ et al (2021) Estimation of current and post-treatment retinal function in chronic central serous chorioretinopathy using artificial intelligence. Sci Rep 11:20446. https:\/\/doi.org\/10.1038\/s41598-021-99977-4","journal-title":"Sci Rep"},{"key":"6698_CR19","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1097\/IAE.0000000000002445","volume":"40","author":"KS Asano","year":"2020","unstructured":"Asano KS, Asaoka R, Asano S et al (2020) \u00a0Elongated photoreceptor outer segment length and prognosis of chronic central serous chorioretinopathy. Retina 40:750\u2013757. https:\/\/doi.org\/10.1097\/IAE.0000000000002445","journal-title":"Retina"},{"key":"6698_CR20","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s00417-022-05905-1","volume":"261","author":"R Funatsu","year":"2023","unstructured":"Funatsu R, Sonoda S, Terasaki H et al (2023) Choroidal morphologic features in central serous chorioretinopathy using ultra-widefield optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 261:971\u2013979. https:\/\/doi.org\/10.1007\/s00417-022-05905-1","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6698_CR21","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.oret.2020.03.024","volume":"4","author":"H Matsumoto","year":"2020","unstructured":"Matsumoto H, Hoshino J, Mukai R et al (2020) Vortex Vein Anastomosis at the Watershed in Pachychoroid Spectrum diseases. Ophthalmol Retina 4:938\u2013945. https:\/\/doi.org\/10.1016\/j.oret.2020.03.024","journal-title":"Ophthalmol Retina"},{"key":"6698_CR22","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/eye.2009.193","volume":"24","author":"V Gupta","year":"2010","unstructured":"Gupta V, Gupta P, Dogra MR, Gupta A (2010) Spontaneous closure of retinal pigment epithelium microrip in the natural course of central serous chorioretinopathy. Eye 24:595\u2013599. https:\/\/doi.org\/10.1038\/eye.2009.193","journal-title":"Eye"},{"key":"6698_CR23","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1097\/IAE.0000000000002580","volume":"40","author":"J Han","year":"2020","unstructured":"Han J, Cho NS, Kim K et al (2020) Fundus autofluorescence patterns in central serous chorioretinopathy. Retina 40:1387\u20131394. https:\/\/doi.org\/10.1097\/IAE.0000000000002580","journal-title":"Retina"},{"key":"6698_CR24","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0161-6420(02)01770-0","volume":"110","author":"FG Holz","year":"2003","unstructured":"Holz FG, Jorzik J, Schutt F et al (2003) Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic therapy eligibility (FLAP-study). Ophthalmology 110:400\u2013405. https:\/\/doi.org\/10.1016\/S0161-6420(02)01770-0","journal-title":"Ophthalmology"},{"key":"6698_CR25","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.6009\/jjrt.66.1485","volume":"66","author":"H Nishiura","year":"2010","unstructured":"Nishiura H (2010) A robust statistic AC\u2081 for assessing inter-observer agreement in reliability studies. Nihon Hoshasen Gijutsu Gakkai Zasshi 66:1485\u20131491. https:\/\/doi.org\/10.6009\/jjrt.66.1485","journal-title":"Nihon Hoshasen Gijutsu Gakkai Zasshi"},{"key":"6698_CR26","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/s0002-9394(00)00605-x","volume":"130","author":"SM Friedman","year":"2000","unstructured":"Friedman SM, Margo CE (2000) Choroidal neovascular membranes: reproducibility of angiographic interpretation. Am J Ophthalmol 130:839\u2013841. https:\/\/doi.org\/10.1016\/s0002-9394(00)00605-x","journal-title":"Am J Ophthalmol"},{"key":"6698_CR27","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/sim.1047","volume":"21","author":"G Heinze","year":"2002","unstructured":"Heinze G, Schemper M (2002) A solution to the problem of separation in logistic regression. Stat Med 21:2409\u20132419. https:\/\/doi.org\/10.1002\/sim.1047","journal-title":"Stat Med"},{"key":"6698_CR28","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1002\/sim.1742","volume":"23","author":"LM Sullivan","year":"2004","unstructured":"Sullivan LM, Massaro JM, D\u2019Agostino RB, Sr (2004) Presentation of multivariate data for clinical use: the Framingham Study risk score functions. Stat Med 23:1631\u20131660. https:\/\/doi.org\/10.1002\/sim.1742","journal-title":"Stat Med"},{"key":"6698_CR29","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1167\/iovs.02-0633","volume":"44","author":"T Sakai","year":"2003","unstructured":"Sakai T, Calderone JB, Lewis GP et al (2003) Cone photoreceptor recovery after experimental detachment and reattachment: an immunocytochemical, morphological, and electrophysiological study. Invest Ophthalmol Vis Sci 44:416\u2013425. https:\/\/doi.org\/10.1167\/iovs.02-0633","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6698_CR30","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/0002-9394(68)91524-9","volume":"66","author":"AJ Kroll","year":"1968","unstructured":"Kroll AJ, Machemer R (1968) Experimental retinal detachment in the owl monkey. 3. Electron microscopy of retina and pigment epithelium. Am J Ophthalmol 66:410\u2013427. https:\/\/doi.org\/10.1016\/0002-9394(68)91524-9","journal-title":"Am J Ophthalmol"},{"key":"6698_CR31","first-page":"927","volume":"24","author":"PA Erickson","year":"1983","unstructured":"Erickson PA, Fisher SK, Anderson DH et al (1983) Retinal detachment in the cat: the outer nuclear and outer plexiform layers. Invest Ophthalmol Vis Sci 24:927\u2013942","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6698_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1167\/iovs.62.3.25","volume":"62","author":"KX Cheong","year":"2021","unstructured":"Cheong KX, Barathi VA, Teo KYC et al (2021) Choroidal and retinal changes after systemic adrenaline and photodynamic therapy in non-human Primates. Invest Ophthalmol Vis Sci 62:25. https:\/\/doi.org\/10.1167\/iovs.62.3.25","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6698_CR33","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1167\/iovs.05-0838","volume":"47","author":"R Tzekov","year":"2006","unstructured":"Tzekov R, Lin T, Zhang K-M et al (2006) Ocular changes after photodynamic therapy. Invest Ophthalmol Vis Sci 47:377\u2013385. https:\/\/doi.org\/10.1167\/iovs.05-0838","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6698_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/archopht.122.1.37","volume":"122","author":"E Ergun","year":"2004","unstructured":"Ergun E, Tittl M, Stur M (2004) Photodynamic therapy with verteporfin in subfoveal choroidal neovascularization secondary to central serous chorioretinopathy. Arch Ophthalmol 122:37\u201341. https:\/\/doi.org\/10.1001\/archopht.122.1.37","journal-title":"Arch Ophthalmol"},{"key":"6698_CR35","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1097\/IAE.0000000000001750","volume":"38","author":"E Peiretti","year":"2018","unstructured":"Peiretti E, Caminiti G, Serra R et al (2018) Anti-vascular endothelial growth factor therapy versus photodynamic therapy in the treatment of choroidal neovascularization secondary to central serous chorioretinopathy. Retina 38:1526\u20131532. https:\/\/doi.org\/10.1097\/IAE.0000000000001750","journal-title":"Retina"},{"key":"6698_CR36","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s10384-008-0613-z","volume":"53","author":"PY Lee","year":"2009","unstructured":"Lee PY, Kim KS, Lee WK (2009) Severe choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chronic central serous chorioretinopathy. Jpn J Ophthalmol 53:52\u201356. https:\/\/doi.org\/10.1007\/s10384-008-0613-z","journal-title":"Jpn J Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06698-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-024-06698-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06698-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T19:23:14Z","timestamp":1743362594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-024-06698-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6698"],"URL":"https:\/\/doi.org\/10.1007\/s00417-024-06698-1","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,22]]},"assertion":[{"value":"10 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of Kagoshima University (no. 170283) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Since this study was a retrospective study, obtaining informed consent was waived in the study. This design is approved by the Ethics Committee of Kagoshima University (no. 170283).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript. Taiji Sakamoto- although the co-author is an editor of the journal, there was no involvement with the peer review process for this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}